首页> 美国卫生研究院文献>Neuropsychiatric Disease and Treatment >Interaction between paliperidone extended release and TS-1® an oral anticancer drug containing a 5-fluorouracil derivative in a schizophrenic patient
【2h】

Interaction between paliperidone extended release and TS-1® an oral anticancer drug containing a 5-fluorouracil derivative in a schizophrenic patient

机译:帕潘立酮缓释与精神分裂症患者TS-1®(一种含有5-氟尿嘧啶衍生物的口服抗癌药物)之间的相互作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Until now there has been no information available on drug interaction between paliperidone and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative. The patient in the case presented here was a 39-year-old man with a 15-year history of schizophrenia. The patient’s usual treatment of 2 mg/day of risperidone was changed to 3 mg/day of paliperidone extended release. He experienced worsening psychotic symptoms after switching from risperidone to paliperidone while he was also receiving TS-1. Retrospective analyses showed plasma concentration of paliperidone was consistently lower during the treatment with TS-1 than without TS-1. This case suggests there is drug interaction between paliperidone extended-release tablets and TS-1.
机译:迄今为止,尚无关于帕潘立酮与TS-1 ®(一种含有5-氟尿嘧啶衍生物的口服抗癌药)之间的药物相互作用的信息。在此例中,该患者为一名精神分裂症病史为15年的39岁男子。患者通常将利培酮每天2 mg的治疗更改为帕潘立酮缓释3 mg / day。从利培酮转为帕潘立酮后,他还经历了TS-1期间的精神病症状恶化。回顾性分析显示,用TS-1治疗期间帕潘立酮的血浆浓度始终低于未使用TS-1的情况。这种情况表明帕潘立酮缓释片和TS-1之间存在药物相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号